feed,title,long_url,short_url
Benzinga,Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges,https://benzinga.com/analyst-ratings/analyst-color/23/10/35294513/cautious-optimism-for-bluebird-bios-sickle-cell-therapy-analyst-sees-financial-chal,https://da.gd/1tw2zN
